Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors
19 Luglio 2021 - 1:00PM
Pluristem Therapeutics Inc.
(Nasdaq: PSTI) (TASE: PSTI), a leading
biotechnology company, today announced the Board of Director
appointments of Prof. Varda Shalev, a physician, medical
researcher, and Professor of Medicine at the Tel Aviv University’s
School of Public Health, and Mr. Doron Birger, a high-tech industry
executive with a background in bringing groundbreaking products to
market.
Prof. Shalev has more than 30 years of
experience working in clinical environments and research settings
at the intersection of health and technology. She was the founder
and Chief Executive Officer of the KSM Institute of Research and
Innovation and Maccabitech, the epidemiological and clinical
research arm of Israel’s Maccabi Healthcare Services, where she
established the largest biobank in Israel and developed a
computerized system for predicting the risk of colon cancer in
patients using a database of two million people. This work led
Maccabi Healthcare Services to win the Director General of the
Ministry of Health's Excellence in Logistics in Health Systems
award. Prof. Shalev founded the Department of Medical Informatics
at Maccabi Healthcare Services and was the head of Primary Care
division of Maccabi Healthcare Services.
Prof.Shalev is Chief Medical Officer and
co-founder of the digital health startup, Alike, which is
developing an artificial intelligence-based platform to empower
patients to track their own health conditions. In addition to
informatics and predictive analytics, Prof. Shalev’s research
expertise includes epidemiology. She has authored more than 250
publications in peer-reviewed journals and was included in the
Marker newspaper’s list of “100 Most Influential People.” Prof.
Shalev earned her medical degree from Ben-Gurion University of
the Negev, School of Medicine, her Master of Public Health
Administration from Clark University in the United States
and completed her post-doctoral fellowship in Medical Informatics
at Johns Hopkins.
Mr. Birger is a prominent business leader with
more than 30 years of experience in the Israeli high-tech sector as
a chief executive officer, board chairman, director, and advisor to
several private and publicly traded firms, with an emphasis in the
life science industry.
Mr. Birger served as the president and Chief
Executive Officer of Elron from 2002 to 2009. At Elron, he
successfully led the development and acceleration of numerous
cutting-edge technology firms, including multiple mergers and
public offerings. He currently chairs several technology companies,
including Sight Diagnostic, Ultrasight, Nurami, Matricelf (TASE:
MTLF), and Intelicanna (TASE: INTL).
Mr. Birger was also the Chairman of the Board at
Given Imaging from 2002 to 2007, and a director until it was sold
to Covidien in 2014. From 1978 to 2001, Mr. Birger was Chief
Financial Officer at several companies from various sectors,
including the Chief Financial Officer of Elron from 1994-2001. He
is currently a director in a variety of medical device and advanced
technology companies, including IceCure (TASE: ICCM), Citrine
Global (OTCQB: CTGL), Kadimastem (TASE: KDST), HeraMED (ASX: HMD)
Vibrant, and Netive Haor. Mr. Birger earned his bachelor’s degree
and Master of Economics from the Hebrew University, Jerusalem.
“By harnessing the regenerative power of
placenta cells using our unique bioreactor for cell expansion,
Pluristem believes that it is poised to unlock a new generation of
medical treatments,” said Pluristem Executive Chairman of the
Board, Zami Aberman. “Prof. Shalev and Mr. Birger both bring unique
expertise and experience that we believe will provide invaluable
insight as we move our product candidate pipelines forward. Their
combined 60 years of life science experience, both clinical and
commercial, are perfectly aligned for Pluristem’s mission to
potentially bring its PLX cells to market and reach patients around
the world. Pluristem’s strategic goals will be served well by their
skillsets and counsel.”
About
Pluristem Therapeutics
Pluristem is pushing the boundaries of science
and engineering to reimagine pharmacological treatments and improve
the standard of care. The Company’s cell therapies advance the
field of regenerative medicine, with potentially groundbreaking
applications for treating damaged muscle, hematology deficiencies,
and inflammation. Pluristem sources its therapeutic cells from the
placenta, an ethically accepted and potent source. Cells are easy
to collect and do not require blood or tissue matching. Cells from
one placenta can treat 20,000 patients. The Company’s manufacturing
platform, the bioreactor, is a patented and validated
state-of-the-art 3D cell expansion system, designed to mimic the
human body. Pluristem’s method is uniquely accurate,
cost-effective, and consistent batch-to-batch.
Safe Harbor Statement
This press release contains express or implied
forward-looking statements within the Private Securities Litigation
Reform Act of 1995 and other U.S. Federal securities laws. For
example, Pluristem is using forward-looking statements when it
discusses its belief that it is poised to unlock a new generation
of medical treatments and that its new directors will enhance the
Board's strategic goals in preparation for future growth and
commercialization endeavors. These forward-looking statements and
their implications are based on the current expectations of the
management of Pluristem only, and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: changes in technology and market requirements;
Pluristem may encounter delays or obstacles in launching and/or
successfully completing its clinical trials; Pluristem’s products
may not be approved by regulatory agencies, Pluristem’s technology
may not be validated as it progresses further and its methods may
not be accepted by the scientific community; Pluristem may be
unable to retain or attract key employees whose knowledge is
essential to the development of its products; unforeseen scientific
difficulties may develop with Pluristem’s process; Pluristem’s
products may wind up being more expensive than it anticipates;
results in the laboratory may not translate to equally good results
in real clinical settings; results of preclinical studies may not
correlate with the results of human clinical trials; Pluristem’s
patents may not be sufficient; Pluristem’s products may harm
recipients; changes in legislation may adversely impact Pluristem;
inability to timely develop and introduce new technologies,
products and applications; loss of market share and pressure on
pricing resulting from competition, which could cause the actual
results or performance of Pluristem to differ materially from those
contemplated in such forward-looking statements. Except as
otherwise required by law, Pluristem undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time
with the Securities and Exchange Commission.
Contact:
Dana Rubin Director of Investor Relations
+972-74-7107194 danar@pluristem.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/35e041c8-fdc0-4ae8-8ad8-666d2908b199
Grafico Azioni Pluristem Therapeutics (NASDAQ:PSTI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Pluristem Therapeutics (NASDAQ:PSTI)
Storico
Da Giu 2023 a Giu 2024